Immuneering Corporation will host a conference call on June 17 to discuss updates on its Phase 2a trial for IMM-1-104.
Quiver AI Summary
Immuneering Corporation, a clinical-stage oncology company, announced a conference call and live webcast scheduled for June 17, 2025, at 8:00 am ET, to provide updates on its Phase 2a clinical trial of IMM-1-104 for first-line pancreatic cancer patients. The company is dedicated to developing innovative cancer treatments, with IMM-1-104 being an oral, once-daily MEK inhibitor aiming to enhance treatment durability and tolerability for patients with MAPK pathway-driven tumors, particularly pancreatic cancer. The call will be available for live viewing and later archived on Immuneering's website.
Potential Positives
- Immuneering Corporation is providing updates on its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients, indicating progress in its research and development efforts.
- The company's lead product candidate, IMM-1-104, is designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, highlighting its potential significance in oncology.
- The conference call and live webcast format allows for real-time engagement with investors and stakeholders, enhancing transparency and communication regarding the company's developments.
- Immuneering's focus on addressing significant unmet medical needs in pancreatic cancer positions it as a key player in the oncology market, potentially attracting interest and support from investors and partners.
Potential Negatives
- The press release does not provide specific results or updates from the ongoing Phase 2a clinical trial of IMM-1-104, which may lead to investor concerns about the lack of transparency regarding the trial's progress and outcomes.
- The statement mentions that IMM-1-104 is designed for a specific indication (MAPK pathway-driven tumors), which may limit the perception of its market potential if the results do not meet expectations.
- As a clinical-stage company, the reliance on trial outcomes and the announcement of a conference call suggests that the company may not have other significant developments to share, raising concerns about the pace of their overall pipeline advancement.
FAQ
What is the conference call about?
The conference call will provide updates on Immuneering's Phase 2a clinical trial of IMM-1-104 in pancreatic cancer patients.
When will the conference call take place?
The conference call is scheduled for June 17, 2025, at 8:00 am ET.
How can I access the conference call?
The conference call will be available via live webcast on Immuneering's Investor Relations website.
What is IMM-1-104?
IMM-1-104 is an oral, once-daily deep cyclic inhibitor of MEK, targeting MAPK pathway-driven tumors like pancreatic cancers.
Where can I find more information about Immuneering Corporation?
More information can be found by visiting Immuneering’s official website at www.immuneering.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMRX Hedge Fund Activity
We have seen 14 institutional investors add shares of $IMRX stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 786,537 shares (+3669.9%) to their portfolio in Q1 2025, for an estimated $1,195,536
- PROSIGHT MANAGEMENT, LP removed 190,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $418,000
- ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 177,377 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $269,613
- PRICE T ROWE ASSOCIATES INC /MD/ removed 108,115 shares (-14.1%) from their portfolio in Q1 2025, for an estimated $164,334
- MILLENNIUM MANAGEMENT LLC removed 79,871 shares (-77.6%) from their portfolio in Q1 2025, for an estimated $121,403
- TD ASSET MANAGEMENT INC removed 79,810 shares (-52.9%) from their portfolio in Q1 2025, for an estimated $121,311
- CORIENT PRIVATE WEALTH LLC removed 63,740 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $96,884
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMRX Analyst Ratings
Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 05/07/2025
To track analyst ratings and price targets for $IMRX, check out Quiver Quantitative's $IMRX forecast page.
Full Release
CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.
The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation .
About Immuneering Corporation
Immuneering is a clinical-stage oncology company outpacing cancer to help patients outlive their disease. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Jenna Urban
[email protected]
Investor Contact:
Laurence Watts
619-916-7620
[email protected]
